Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07228689

AI for Onsite Cytology Evaluation in Endoscopic Ultrasound

Artificial Intelligence for Onsite Cytology Evaluation in Endoscopic Ultrasound

Status
Recruiting
Phase
Study type
Observational
Enrollment
200 (estimated)
Sponsor
Orlando Health, Inc. · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The aim of this study is to determine if the widely available artificial intelligence platform ChatGPT can accurately identify the abnormalities present on cytology specimens obtained at EUS-FNB of solid mass lesions in the gastrointestinal tract, in comparison with interpretation by cytopathologists as the gold standard.

Detailed description

The diagnostic accuracy of EUS-guided fine needle biopsy of lesions in the gastrointestinal tract is dependent on the availability of a cytopathologist to render a rapid on-site evaluation (ROSE), with studies showing that the presence of an on-site cytopathologist improves the diagnostic yield, decreases the number of inadequate or unsatisfactory samples, and limits the number of passes required to establish a diagnosis. However, the availability of ROSE is variable across centers and regions, with the availability of onsite cytopathology services limited to a handful of tertiary referral centers in the United States. ChatGPT is a universally available, generative artificial intelligence program developed by OpenAI. The aim of this study is to determine if this AI platform can accurately identify the abnormalities present on cytology specimens obtained at EUS-FNB of solid mass lesions in the gastrointestinal tract, in comparison with interpretation by cytopathologists as the gold standard.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTEUS-guided fine needle biopsyEUS-guided fine needle biopsy of solid mass lesions in the gastrointestinal tract

Timeline

Start date
2025-11-12
Primary completion
2026-12-01
Completion
2027-10-01
First posted
2025-11-14
Last updated
2025-11-14

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT07228689. Inclusion in this directory is not an endorsement.